Quinapril

Quinapril

SCHEMBL994608

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Quinapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ACE known ✓ P12821 16/20 1.00
ABCB11 O95342 2/20 1.00
PDE3A Q14432 1/20 0.80
LMNA P02545 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinapril SCHEMBL15813 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL13575806 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL29380303 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL29846170 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL678447 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL11286555 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL11294979 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL19361887 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL9094436 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL11286551 1.00 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675838-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS Puretecch LYT, Inc. (US) 2020-07-08 EP disclosed
WO-2019046491-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS ARIYA THERAPEUTICS, INC. (US) 2019-03-07 WO disclosed
EP-2736489-A1 COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES Cellworks Research India Private Limited (IN) 2014-06-04 EP disclosed
WO-2013016718-A1 COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES CELLWORKS RESEARCH INDIA PRIVATE LIMITED (IN) 2013-01-31 WO disclosed
US-20120101630-A1 PHARMACEUTICAL PACKAGING AND METHOD FOR DELIVERY OF SAME DAYA MEDICALS, INC. 2012-04-26 US disclosed
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US disclosed
EP-1968967-B1 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS HOFFMANN LA ROCHE (CH) 2011-04-27 EP disclosed
EP-2102214-B1 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS HOFFMANN LA ROCHE (CH) 2011-03-23 EP disclosed
US-7902184-B2 Piperazinyl pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
EP-1957479-B1 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-03-02 EP disclosed
WO-2011011114-A2 PHARMACEUTICAL PACKAGING AND METHOD FOR DELIVERY OF SAME DAYA MEDICALS, INC. (US) 2011-01-27 WO disclosed
WO-2005079772-A2 COMBINATION OF (S)-AMLODIPINE AND AN ACE INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION SEPRACOR INC. (US) 2005-09-01 WO disclosed
WO-2002087503-A2 COMPOSITIONS AND METHODS FOR TREATING COLORECTAL POLYPS AND CANCER VANDERBILT UNIVERSITY (US) 2002-11-07 WO disclosed
WO-2002059343-A2 BIOLOGICAL MARKERS AND DIAGNOSTIC TESTS FOR ANGIOTENSIN CONVERTING ENZYME INHIBITOR- AND VASOPEPTIDASE INHIBITOR-ASSOCIATED ANGIOEDEMA VANDERBILT UNIVERSITY (US) 2002-08-01 WO disclosed